Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mike Mensinger sold 1,115 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $17.89, for a total value of $19,947.35. Following the completion of the sale, the insider now owns 92,904 shares of the company's stock, valued at $1,662,052.56. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Beta Bionics Price Performance
Shares of BBNX traded down $0.47 during trading hours on Friday, hitting $19.08. The stock had a trading volume of 583,609 shares, compared to its average volume of 503,190. The business's 50 day moving average is $13.05. Beta Bionics, Inc. has a 1-year low of $8.89 and a 1-year high of $24.50.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.01).
Hedge Funds Weigh In On Beta Bionics
Hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in Beta Bionics during the 1st quarter valued at about $29,000. Corebridge Financial Inc. acquired a new position in Beta Bionics during the 1st quarter valued at about $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Beta Bionics during the 1st quarter valued at about $95,000. MetLife Investment Management LLC acquired a new position in Beta Bionics during the 1st quarter valued at about $102,000. Finally, Deutsche Bank AG acquired a new position in Beta Bionics during the 1st quarter valued at about $148,000.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on the company. Bank of America assumed coverage on Beta Bionics in a report on Monday, February 24th. They set a "buy" rating for the company. Wolfe Research assumed coverage on Beta Bionics in a research report on Friday, May 30th. They issued an "outperform" rating and a $20.00 price objective for the company. Leerink Partners assumed coverage on Beta Bionics in a research report on Monday, February 24th. They issued an "outperform" rating and a $28.00 price objective for the company. Baird R W raised Beta Bionics to a "hold" rating in a research report on Thursday, February 20th. Finally, Stifel Nicolaus assumed coverage on Beta Bionics in a research report on Monday, February 24th. They issued a "buy" rating and a $25.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Beta Bionics has an average rating of "Moderate Buy" and a consensus target price of $23.13.
Read Our Latest Analysis on BBNX
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
See Also
Before you consider Beta Bionics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.
While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
